Roth Mkm Reaffirms Buy Rating for Gain Therapeutics (NASDAQ:GANX)

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reissued by investment analysts at Roth Mkm in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $7.00 target price on the stock. Roth Mkm’s price target would indicate a potential upside of 340.25% from the stock’s current price.

A number of other equities analysts also recently commented on the company. Roth Capital raised Gain Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a report on Monday, November 25th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $7.25.

Gain Therapeutics Trading Up 1.3 %

GANX opened at $1.59 on Tuesday. The business has a fifty day moving average price of $1.99 and a 200 day moving average price of $1.60. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99. Gain Therapeutics has a 12 month low of $0.89 and a 12 month high of $5.33. The stock has a market capitalization of $42.17 million, a price-to-earnings ratio of -1.45 and a beta of 0.21.

Hedge Funds Weigh In On Gain Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its position in Gain Therapeutics by 48.0% in the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after acquiring an additional 88,236 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Gain Therapeutics by 154.2% in the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after purchasing an additional 72,000 shares during the period. Warberg Asset Management LLC purchased a new position in Gain Therapeutics during the 2nd quarter worth approximately $66,000. Finally, Hohimer Wealth Management LLC purchased a new position in Gain Therapeutics during the 2nd quarter worth approximately $422,000. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.